A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Trial Profile

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Bb 2121 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors bluebird bio; Celgene Corporation
  • Most Recent Events

    • 10 Dec 2017 Results (n=21) presented in a Celgene Corporation Media Release.
    • 16 Nov 2017 According to a Celgene Corporation and bluebird bio Inc media release,Updated data from this study will be presented at the 59th annual meeting of the American Society of Hematology in Atlanta on December 11.
    • 16 Nov 2017 According to a Celgene Corporation and bluebird bio Inc media release, based on the preliminary clinical data from this study bb2121 Anti-BCMA CAR-T Cell Therapy has been granted PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top